Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.45 |
| ▸ | ITGAV | P06756 | 8/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.45 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20575116 | 0.93 | ITGB3 (0.43) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL20575617 | 0.92 | ITGB3 (0.42) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL20574516 | 0.91 | KMT2A (0.41) | SMN1; SMN2ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL20575025 | 0.88 | MEN1 (0.41) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL20574581 | 0.87 | ITGB3 (0.39) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL20575605 | 0.85 | MEN1 (0.42) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL2834278 | 0.85 | ITGB3 (0.63) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL20575108 | 0.83 | ITGB3 (0.42) | ITGB3ITGA2BITGAVSMN1; SMN2ALDH1A1 | |
| SCHEMBL20575157 | 0.83 | ITGB3 (0.41) | ITGB3ITGA2BITGAVITGB1ITGB5 | |
| SCHEMBL4234703 | 0.83 | ITGB3 (0.62) | ITGB3ITGA2BITGAVITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344803-A1 | Methods and Compositions For the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | ITGB3 1/4885ITGA2B 4/4885ITGAV 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.